Screener
CRISPR Therapeutics CRSP PP&E (Net)
PP&E (Net) at other companies
Other financials
Where this comes from
Reported directly by CRISPR Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.
The source filing: CRISPR Therapeutics’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 4:48 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-204188
| Line item | As of / March 31, 2026 | As of / December 31, 2025 |
|---|---|---|
| Marketable securities | 2,018,477 | 1,628,269 |
| Prepaid expenses and other current assets | 6,577 | 9,843 |
| Total current assets | 2,448,362 | 1,985,671 |
| Property and equipment, net | 112,175 | 115,851 |
| Restricted cash | 7,629 | 7,629 |
| Operating lease assets | 128,671 | 131,724 |
| Other non-current assets | 28,983 | 24,368 |
| Total assets | $2,725,820 | $2,265,243 |
Item 1. Financial Statements
FAQ
- What is CRISPR Therapeutics's PP&E (net)?
- CRISPR Therapeutics (CRSP) reported PP&E (net) of $112.18M in Q1 2026.
- How has CRISPR Therapeutics's PP&E (net) changed year-over-year?
- CRISPR Therapeutics's PP&E (net) decreased by 13.3% year-over-year, from $129.43M to $112.18M.
- What is the long-term trend for CRISPR Therapeutics's PP&E (net)?
- Over 5 years (2020 to 2025), CRISPR Therapeutics's PP&E (net) has grown at a 22.4% compound annual growth rate (CAGR), from $42.16M to $115.85M.
- What does PP&E (net) mean?
- Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.
Ask your AI about CRISPR Therapeutics's pp&e (net).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude